Pyrimidine-Based Third-Generation Tyrosine Kinase Inhibitors: A Medicinal Chemistry Perspective

TGTKIs have transformed the therapeutic concept for mutant NSCLC patients and have offered unprecedented efficacy and durability compared to earlier-generation inhibitors.